<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650467</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2012/JBG-02</org_study_id>
    <secondary_id>2012-A00639-34</secondary_id>
    <nct_id>NCT01650467</nct_id>
  </id_info>
  <brief_title>Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms</brief_title>
  <acronym>abl LMC</acronym>
  <official_title>Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the existence of a relationship between the&#xD;
      presence of certain abl polymorphisms (or haplotypes) upon CML diagnosis and the occurrence&#xD;
      of primary resistance to the treatment of CML by imatinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first secondary objective of this study is to identify, in patients not responding to&#xD;
      treatment, possible changes in the polymorphisms of interest during the course of the&#xD;
      disease, reclassifying such polymorphisms as mutations.&#xD;
&#xD;
      The second secondary objective is to compare the control patients in terms of polymorphism&#xD;
      frequency on the nonpathological abl fraction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding is late, unforseeable.&#xD;
  </why_stopped>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>abl genotype</measure>
    <time_frame>baseline ; at diagnosis</time_frame>
    <description>The abl genotype will be determined for all subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>abl genotype</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>The abl genotype will be determined for all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bcr-abl leucemic fraction genotype</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>The bcr-able leucemic fraction genotype will be determined for CML patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bcr-abl leucemic fraction genotype</measure>
    <time_frame>baseline ; at diagnosis</time_frame>
    <description>The bcr-able leucemic fraction genotype will be determined for CML patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abl non-leucemic fraction genotype</measure>
    <time_frame>baseline ; at diagnosis</time_frame>
    <description>The abl non-leucemic fraction genotype will be determined for CML patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abl non-leucemic fraction genotype</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>The abl non-leucemic fraction genotype will be determined for CML patients</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Leukemia, Myeloid, Chronic-Phase</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>60 healthy controls with no hematological pathologies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib optimal response</arm_group_label>
    <description>30 CML patients who are optimal responders to imatinib treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib primary resistance</arm_group_label>
    <description>30 CML patients who have primary resistance to imatinib treatment</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two 7 ml EDTA tubes for genotyping abl and bcr-abl polymorphisms&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will include 60 healthy controls (free of hematologic pathology, seen in genetic&#xD;
        counseling) and stratify the recruitment of patients with CML among 30 patients with&#xD;
        optimal imatinib response and 30 with primary resistance.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have given his/her informed and signed consent&#xD;
&#xD;
          -  The patient must be insured or beneficiary of a health insurance plan&#xD;
&#xD;
        Inclusion Criteria for all CML patients&#xD;
&#xD;
          -  Patients diagnosed with CML&#xD;
&#xD;
          -  Treatment with Imatinib in first-line monotherapy and this for at least 12 months&#xD;
&#xD;
          -  RNA and / or cDNA used for diagnosis correctly stored in the biobank&#xD;
&#xD;
        Inclusion Criteria for CML patients already having undergone a follow-up visit at 12 months&#xD;
&#xD;
          -  RNA and / or cDNA used for diagnosis/follow-up correctly stored in the biobank&#xD;
&#xD;
          -  Cytogenetic results are available&#xD;
&#xD;
          -  Absence of ITK mutation for the primary resistance subgroup&#xD;
&#xD;
          -  Validated compliance&#xD;
&#xD;
        Inclusion Criteria for the optimal response group:&#xD;
&#xD;
          -  bcr-abl typing is less than 0.1% at 12 months&#xD;
&#xD;
        Inclusion criteria for the primary resistance group&#xD;
&#xD;
          -  bcr-abl typings is &gt;1% and/or Philadelphia+ is greater than 0&#xD;
&#xD;
        Inclusion Criteria for the control population&#xD;
&#xD;
          -  Absence of hematologic malignancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient is participating in another study&#xD;
&#xD;
          -  The patient is in an exclusion period determined by a previous study&#xD;
&#xD;
          -  The patient is under judicial protection, under tutorship or curatorship&#xD;
&#xD;
          -  The patient refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to correctly inform the patient&#xD;
&#xD;
          -  The patient is pregnant, parturient, or breastfeeding&#xD;
&#xD;
          -  The patient has a contraindication for a treatment used in this study&#xD;
&#xD;
        Exclusion Criteria for CML patients already having undergone a follow-up visit at 12 months&#xD;
&#xD;
          -  Known or suspected cause for resistance (dose reduced due to intolerance, digestive&#xD;
             disease responsible for malabsorption ...)&#xD;
&#xD;
        Exclusion Criteria for the control population&#xD;
&#xD;
          -  History or suspicion of hemopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Baptiste Gaillard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique du Parc</name>
      <address>
        <city>Castelnau Le Lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abl polymorphisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

